# A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

> **NCT06428019** · PHASE3 · RECRUITING · sponsor: **AbbVie** · enrollment: 170 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Acalabrutinib
- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT06428019
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-05
- **Primary completion:** 2028-03
- **Final completion:** 2028-03
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06428019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06428019, "A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06428019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*